Stay informed with the latest litigation news. Explore now
Rapamycin Derivative For Treating Pancreas Cancer - EP3342411B1
EP3342411
- Application Number
- EP18155724A
- Filing Date
- Feb 18, 2002
- Status
- Opposition Rejected
- Dec 18, 2023
- Grant Date
- Aug 21, 2019
- External Links
- Slate, Register, Google Patents
- Similar Patents facing opposition
Bibliography
The patent EP3342411B1 was granted to Novartis on Aug 21, 2019 following the initial filing on Feb 18, 2002 under the application number EP18155724A . The current legal status of the patent is Opposition Rejected.
Patent Summary
Patent Family New
Patent Oppositions (10)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Get instant alerts for new documents